Abstract
Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia. The median number of prior chemotherapy regimens was 3 (1-5). Treatment was well tolerated up to the maximal doses of temozolomide 200 mg/m2/d times 7 days and cisplatin 100 mg/m2 on day 1. There was one complete remission in this heavily pretreated patient population. Five of 20 (25%) patients demonstrated a significant reduction in bone marrow blasts.
Publication types
-
Clinical Trial, Phase I
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage*
-
Cisplatin / adverse effects
-
Dacarbazine / administration & dosage
-
Dacarbazine / adverse effects
-
Dacarbazine / analogs & derivatives*
-
Drug Resistance, Neoplasm / drug effects
-
Female
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Male
-
Middle Aged
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Recurrence
-
Salvage Therapy
-
Temozolomide
-
Treatment Failure
-
Young Adult
Substances
-
Dacarbazine
-
Cisplatin
-
Temozolomide